FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Designing, validation and evaluation of an mHealth app for prenatal health promotion based on the unified theory of acceptance and use of technology: A mixed methods study protocol. PMID 40730798 · Sci Rep · 2025-Jul-29 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial. PMID 40717193 · J Egypt Natl Canc Inst · 2025-Jul-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups. PMID 40239914 · Cancer Lett · 2025-Jul-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Identifying and assessing the capacity and experience of trial sites in low- and middle-income countries for high-quality randomised drug trials in maternal and perinatal health. PMID 40716797 · BMJ Glob Health · 2025-Jul-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. PMID 40684778 · Lancet · 2025-Jul-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial. PMID 40713037 · BMJ Open · 2025-Jul-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-directed behavioral-physical interventions to alleviate acute hiccups associated with chemotherapy: a prospective randomized controlled trial. PMID 40711569 · Support Care Cancer · 2025-Jul-25 The study is a randomized trial in oncology patients, but it fails eligibility because: 1) the intervention is non-pharmacological (behavioral-physical), not a drug-containing intervention, 2) the primary endpoint is not a time-to-event efficacy endpoint relevant to oncologic treatment (like OS/PFS), and 3) it is not established as a Phase III or definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial). PMID 40159243 · Circ J · 2025-Jul-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| REPAIR_GETUG P16 relapse in previously irradiated prostate bed: a phase I/II study of stereotactic ablative reirradiation potentiated by a metformine study protocol. PMID 40707156 · BMJ Open · 2025-Jul-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines. PMID 40707153 · BMJ Open · 2025-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ivermectin to Control Malaria - A Cluster-Randomized Trial. PMID 40700688 · N Engl J Med · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. PMID 40548694 · N Engl J Med · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis. PMID 40473149 · J Ethnopharmacol · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial. PMID 40702551 · J Transl Med · 2025-Jul-23 The record describes a randomized, multicenter trial with a drug-containing intervention and primary time-to-event endpoints (OS, PFS), but the abstract and metadata do not explicitly state the trial phase. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Telehealth and Online Cognitive Behavioral Therapy-Based Treatments for High-Impact Chronic Pain: A Randomized Clinical Trial. PMID 40699570 · JAMA · 2025-Jul-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial. PMID 40696391 · Lipids Health Dis · 2025-Jul-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. PMID 40392667 · J Am Coll Cardiol · 2025-Jul-22 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. PMID 40305657 · Blood Adv · 2025-Jul-22 The abstract describes a secondary analysis of a subgroup (patients ≥70 years) from a Phase III randomized trial (BMT CTN 1703). While it is a human oncology RCT with a time-to-event endpoint (GRFS), the interventions (PTCy, Tac/MTX) are immunosuppressive regimens for GVHD prophylaxis, not a drug-containing intervention for the hematologic malignancy itself. The endpoint (GRFS) is a composite of GVHD control and relapse, not a traditional drug-efficacy endpoint like OS or PFS for the cancer. Therefore, it does not meet the criterion for a 'drug-containing intervention' for the malignant neoplasm. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. PMID 40266025 · Blood Adv · 2025-Jul-22 The record is a pooled analysis of four randomized controlled trials (RESONATE, RESONATE-2, iLLUMINATE, HELIOS), but the specific trials are not individually described with sufficient detail (e.g., phase, primary endpoint, drug intervention for the trial itself). The analysis focuses on the association of statin use with outcomes, which is a secondary analysis, not the original primary efficacy report of a trial. Additionally, while statin use is analyzed, the primary drug intervention in the trials is ibrutinib, but the report itself is not a primary trial result report; it is a post-hoc/pooled analysis of existing trial data. The phase of the trials is not explicitly stated in the metadata as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. PMID 40448574 · J Clin Oncol · 2025-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. PMID 40448572 · J Clin Oncol · 2025-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA-IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial. PMID 40682106 · BMC Med · 2025-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Ecological Momentary Assessment Participation on Short-Term Smoking Cessation: quitSTART Ecological Momentary Assessment Incentivization Randomized Trial. PMID 40680166 · J Med Internet Res · 2025-Jul-18 The study is a randomized controlled trial in humans, but it is not an oncology trial (smoking cessation), does not involve a drug intervention, and does not use a time-to-event endpoint (primary outcome is abstinence at fixed time points, not a survival or time-to-event analysis). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. PMID 39960062 · Clin Infect Dis · 2025-Jul-18 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Intraoperative parathyroid hormone monitoring to guide surgery in renal hyperparathyroidism (PEREGRINE): a protocol for a randomised multiarm surgical pilot trial. PMID 40675640 · BMJ Open · 2025-Jul-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis. PMID 40673584 · N Engl J Med · 2025-Jul-17 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study. PMID 40671096 · Radiat Oncol · 2025-Jul-16 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Indocyanine green fluorescence in pelvic lymph node dissection during laparoscopic radical prostatectomy: a randomized controlled trial. PMID 40670731 · Updates Surg · 2025-Jul-16 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081. PMID 40664454 · J Immunother Cancer · 2025-Jul-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Effect of Forgiveness Psychoeducation on Forgiveness, Self-Compassion and Death Anxiety in Cancer Patients: A Randomized Controlled Trial. PMID 40663159 · Omega (Westport) · 2025-Jul-15 The record reports a randomized controlled trial in oncology patients, but it tests a non-drug intervention (forgiveness psychoeducation) and its endpoints are psychological outcomes, not time-to-event efficacy measures. Therefore, it does not meet the criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative administration of CBM588 in colorectal cancer radical surgery: A single-center, randomized controlled trial. PMID 40633539 · Cell Rep Med · 2025-Jul-15 The study is a Phase IV randomized controlled trial in colorectal cancer with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints are postoperative functional recovery and immune status, not survival or progression-based outcomes. Therefore, it is ineligible for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800). PMID 40614118 · Cancer · 2025-Jul-15 The record is excluded because it does not meet the required phase criterion (one trial is Phase 3b, the other is Phase 2, and the combined record is not a single definitive Phase III/IIIb or Phase II/III trial) and lacks a time-to-event efficacy endpoint. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis from the Phase 3 RAISE study. PMID 40450840 · J Neurol Sci · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Outcomes for Glabellar Line Improvement and Satisfaction With the RelabotulinumtoxinA Ready-to-Use Liquid Formulation: Data From the Phase 3 READY-1 Trial. PMID 40242960 · Aesthet Surg J · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Esaxerenone Plus a Renin-Angiotensin System Inhibitor or Calcium Channel Blocker for Nocturnal Hypertension: A Post Hoc Analysis. PMID 40178088 · Am J Hypertens · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial. PMID 40079683 · Int J Cancer · 2025-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. PMID 39949051 · Gut Liver · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. PMID 39607675 · J Clin Endocrinol Metab · 2025-Jul-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. PMID 40678712 · World J Gastroenterol · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast cancer survivors (PACHA): protocol for a pilot cluster-randomized controlled trial. PMID 40660375 · Pilot Feasibility Stud · 2025-Jul-14 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Reasons for refusing high tibial osteotomy and the impact of virtual reality-based patient education: a prospective single-centre study. PMID 40660307 · J Orthop Surg Res · 2025-Jul-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial. PMID 40658949 · JMIR Res Protoc · 2025-Jul-14 This is a protocol for a pilot randomized trial of a non-drug, digital cognitive behavioral therapy intervention for sleep disturbance in breast cancer survivors. It is not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, does not report efficacy results, and has no time-to-event primary or key secondary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Influence of different photobiomodulation protocols on the prevention of chemotherapy-induced dysgeusia in breast cancer patients treated with Doxorubicin-Cyclophosphamide: a phase III, randomized, triple-blinded non-inferiority clinical trial. PMID 40658227 · Support Care Cancer · 2025-Jul-14 The record is a Phase III randomized trial in oncology with a drug intervention, but it does not have a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints are toxicity, quality of life, and other non-survival outcomes. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Surgery or radiotherapy for early-stage cancer study (SORT) target trial protocol: stereotactic ablative radiotherapy (SABR) with curative intent versus surgical resection for early-stage non-small cell lung cancer (NSCLC). PMID 40659399 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Impact of proactively inviting people with advanced cancer to talk about the end of life: a randomised clinical trial protocol. PMID 40659391 · BMJ Open · 2025-Jul-13 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. PMID 40652143 · J Cancer Res Clin Oncol · 2025-Jul-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. PMID 40570869 · Lancet · 2025-Jul-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| STUDY PROTOCOL FOR A DUAL-CENTER RANDOMIZED CONTROLLED TRIAL COMPARING LAPAROSCOPIC AND OPEN 'MINOR' LIVER RESECTIONS IN UKRAINIAN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES. PMID 40674155 · Exp Oncol · 2025-Jul-11 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study. PMID 40641116 · Br J Psychiatry · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. PMID 40100744 · J Infect Dis · 2025-Jul-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |